Publications
CASE REPORT: Canine intestinal mucinous carcinoma and immunotherapy
Canine intestinal carcinoma: What role for autologous immunotherapy APAVAC®?
CASE REPORT: APAVAC® immunotherapy integrated into a multimodal strategy for the treatment of canine osteosarcoma
Multimodal and Minimally Invasive Strategy for Canine Appendicular Osteosarcoma: Innovative Approach Integrating APAVAC® Immunotherapy A Common Tumor in Dogs
CASE REPORT: Efficacity of APAVAC® immunotherapy in the adjuvant treatment of canine mucosal melanoma
Canine Mucosal Melanoma: Efficacity of the immunotherapy APAVAC®
The 3 keys to autologous immunotherapy APAVAC® (3. Hydroxyapatite)
Autologous therapeutic vaccine APAVAC®: Why hydroxyapatite particules ?
The 3 keys to autologous immunotherapy APAVAC® (2. Heat Shock proteins)
Autologous therapeutic vaccine APAVAC®: Why Heat Shock Proteins ?
The 3 keys to autologous immunotherapy APAVAC® (1. Tumor Antigens)
Autologous therapeutic vaccine APAVAC®: Why tumour antigens?
Autologous therapeutic vaccine APAVAC®: Lymph node system role
What role do lymph nodes play in the immune response?
CASE REPORT: equine melanoma
APAVAC® autologous immunotherapy useful and non-toxic in the treatment of equine melanoma
APAVAC® autologous Vaccine Which indications for which animals ?
Marketed 10 years ago for canine lymphoma, as a "personalised" immunotherapy in adjuvant medical treatment to chemotherapy, APAVAC® has already been used to treat more than 1,000 animals. But other species and other indications have also benefited from this treatment.
Newsletter: Canin Osteosarcoma
Anticipate the possibility of APAVAC® Face to an osteosarcoma?
how to preparer autologous anti-tumor vaccine ?
Professor Laura MARCONATO's team at the University of Bologna has shared with us their experience in preparing treatment for canine lymphoma.